<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140201</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetic Retinopathy</org_study_id>
    <nct_id>NCT04140201</nct_id>
  </id_info>
  <brief_title>Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients</brief_title>
  <official_title>Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alaa Hassan ElBaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator study evaluate the effect of different lipid lowering agents on the
      progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator study compare the effect of lipid lowering agent on the enhancement of
      visual acuity and on reduction of macular edema in patients with diabetic retinopathy and
      also compare their effect on reduction of cardiovascular risk on diabetic patients via
      assessment of ASCVD risk score
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 80 participants will be evaluated through reduction of macular edema</measure>
    <time_frame>18 weeks</time_frame>
    <description>assessed by ocular coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 80 participants will be evaluated through reduction of cardiovascular risk</measure>
    <time_frame>18 weeks</time_frame>
    <description>assessed by ASCVD risk score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Receive oral hypoglycemic +omega 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eicosapentanoic acid + standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receive oral hypoglycemic +statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin + standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receive oral hypoglycemic +fibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate +standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receive oral hypoglycemic only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>Drugs that lower lipid level</description>
    <arm_group_label>Receive oral hypoglycemic +statin</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 200mg</intervention_name>
    <description>Drugs that lower lipid levels</description>
    <arm_group_label>Receive oral hypoglycemic +fibrate</arm_group_label>
    <other_name>Fibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acid</intervention_name>
    <description>Drugs that lower lipid levels</description>
    <arm_group_label>Receive oral hypoglycemic +omega 3</arm_group_label>
    <other_name>n3 FA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2diabetes

          -  Non proliferative diabetic retinopathy

        Exclusion Criteria:

          -  Uncontrolled glycemic level

          -  proliferative diabetic retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Alaa Hassan ElBaz</investigator_full_name>
    <investigator_title>Assistant lecturer at beni suef university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

